Antibodies

15 Jun 2019 Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
15 Jun 2019 Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
14 Jun 2019 Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
14 Jun 2019 FDA Approves Amgen And Allergan's KANJINTITM (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
14 Jun 2019 UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
13 Jun 2019 Update on Etigilimab (TIGIT) Partnership
13 Jun 2019 Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
13 Jun 2019 Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab
13 Jun 2019 First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma
13 Jun 2019 Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
12 Jun 2019 BioInvent publishes first clinical data from BI-1206 Phase l/lla trials
12 Jun 2019 MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
12 Jun 2019 New Subcutaneous Formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) Shows Positive Results for the Treatment of Rheumatoid Arthritis (RA) In Data Presented at the Annual European Congress of Rheumatology (EULAR 2019)
12 Jun 2019 FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
11 Jun 2019 New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
11 Jun 2019 FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
11 Jun 2019 Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
10 Jun 2019 FDA Grants Genentech’s Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma
10 Jun 2019 Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
10 Jun 2019 A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
07 Jun 2019 New report about bispecific antibodies engaging T-cells and NK cells
07 Jun 2019 Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting
06 Jun 2019 AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
06 Jun 2019 Innate pharma enrolls first patient in IPH4102 TELLOMAK phase II study
06 Jun 2019 Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top